Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

29.44 -0.29 (-0.98%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Travere Therapeutics to Report Second Quarter 2023 Financial Results

July 20, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation ↗

July 17, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

July 17, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Travere Therapeutics ↗

June 07, 2023

Via Benzinga

11 Analysts Have This to Say About Travere Therapeutics ↗

May 22, 2023

Via Benzinga

Recap: Travere Therapeutics Q1 Earnings ↗

May 04, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

3 Small-Cap Stocks That Could Be Big-Time Winners ↗

July 22, 2023

These stocks come with significant risks. But they could generate huge returns over time.

Via The Motley Fool

Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan ↗

July 21, 2023

Travere Therapeutics shares have lost nearly 30% since early May.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗

July 21, 2023

Via Benzinga

Expert Ratings for Travere Therapeutics ↗

July 18, 2023

Via Benzinga

Earnings Outlook For Travere Therapeutics ↗

May 03, 2023

Via Benzinga

Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

July 17, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire ↗

July 05, 2023

Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.

Via Investor's Business Daily

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

June 08, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

3 Biotech Stocks That Could Skyrocket in the Next 12 Months ↗

June 07, 2023

These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.

Via InvestorPlace

Travere Therapeutics to Present at Upcoming Investor Conferences

June 01, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

May 31, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

3 Biotech Stocks With Blockbuster Potential ↗

May 24, 2023

Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗

May 22, 2023

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 11, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports First Quarter 2023 Financial Results

May 04, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 02, 2023

Via Benzinga

Chegg, Community Health Systems, Metropolitan Bank And Other Big Stocks Moving Lower On Tuesday ↗

May 02, 2023

U.S. stocks traded lower, with the Dow Jones losing around 477 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 02, 2023

From The Schall Law Firm

Via Business Wire

Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test ↗

May 02, 2023

Travere was testing a treatment for FSGS, a condition that causes kidney scarring.

Via Investor's Business Daily

Travere Therapeutics' Rare Kidney Disease Drug Disappoints In Phase 3 Study, Analyst Says Efficacy Trends Suggest Potential Path Forward ↗

May 02, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) announced

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 02, 2023

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Contact Us

Contact Us

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

All News about Travere Therapeutics, Inc. - Common Stock